Relapse is a major problem after allogeneic transplantation in children with acute B-lineage lymphoblastic leukemias (ALL) and lymphomas and additional therapeutic strategies are needed to increase graft versus leukemia effects without inducing graft versus host disease (GvHD). Several studies have shown the efficacy of a humanized CD20 antibody (rituximab) for treatment of CD20 þ malignancies together with conventional chemotherapy but less is known about its post transplant usefulness. We studied the ability of rituximab to mediate antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) with effector cells and complement from patients who were transplanted with T-cell-depleted grafts from unrelated or mismatched related donors. Highest lytic activity (ADCC) was observed against leukemia-derived MHH4 cells and Burkitt's lymphoma-derived Raji cells in the first months after transplantation, corresponding to the high percentage of regenerating CD56 þ CD16 þ cells. Moreover, primary cryopreserved ALL-blasts from a pediatric patient were also efficiently lysed. Increased lysis was obtained after stimulation with interleukin-2. Combination of ADCC and CDC had additive effects. These findings encourage clinical trials on the use of rituximab for improving minimal residual disease control and relapse prevention after allogeneic high-risk transplantation in the small group of pediatric patients with CD20 þ leukemias/ lymphomas. Bone Marrow Transplantation (2005) 36, 91-97.
Transplantation of allogeneic hematopoietic stem cells is the only potentially curative treatment option for several high-risk acute lymphoblastic leukemias (ALL) and lymphomas of childhood. Due to the fact that only 30% of patients have a histocompatible sibling, alternative (matched unrelated or mismatched-related) donors must be chosen for many patients. 1 Graft versus host disease (GvHD) and GvHD-related mortality has been reduced significantly in those transplantations by positive selection of CD34 þ progenitors 2, 3 and other T-cell depletion techniques, but leukemic relapses still remain a major problem. 4, 5 Several clinical trials have demonstrated the efficacy of rituximab, a chimeric anti-CD20 monoclonal antibody, for the treatment of CD20 þ human leukemias or lymphomas [6] [7] [8] and ADCC and CDC are generally accepted to be important mechanisms for tumor cell elimination. [9] [10] [11] [12] In contrast, little is known about the potential usefulness of rituximab after allogeneic transplantation. So far, in one recent study a favorable outcome for adult patients with non-Hodgkin's lymphoma after post transplant treatment with rituximab was shown, but we know of no data on pediatric patients. 13 Consequently, we investigated whether rituximab would exert ADCC and CDC against pediatric CD20 þ leukemic blasts with effector cells and complement from children after allogeneic transplantation. Since all patients received T-cell-depleted transplants from alternative donors, the role of natural killer (NK) cells was of special interest. Our aim was to provide in vitro data that encourage the use of rituximab as an immunotherapeutic strategy for elimination of minimal residual leukemic cells in this intensively pretreated patient group.
Patients, materials and methods

Patients
ADCC or CDC reactions with a chimeric CD20 antibody (Mabthera s Roche, Basel, Switzerland) against CD19 þ / CD20 þ MHH4 and/or Raji cells were performed with ficollized blood samples from a total of 19 patients obtained within four periods after transplantation (1st period: 1-4 months, 2nd period: 5-11 months; 3rd period: 12-24 months, 4th period: 424 months). In nine additional patients, ADCC and/or CDC was measured against cryopreserved primary B-lineage acute lymphoblastic leukemic blasts. The study was approved by the local ethics committee. The diagnoses were: acute lymphoblastic leukemia (ALL, n ¼ 14), myeloid leukemias (AML, n ¼ 3, CML, n ¼ 3) and myelodysplastic syndromes (MDS, n ¼ 1) and several nonmalignant diseases (n ¼ 7). In all, 19 patients had closely matched unrelated donors and nine had mismatched-related donors. Ages ranged from 0.4 to 18.3 years with a median age of 8.6 years. The myeloablative conditioning regimens were based on either total body irradiation or busulfan. Nonmyeloablative regimens were not used. The CliniMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany) was used for positive selection of CD34 þ /CD133 þ peripheral stem cells or for depletion of CD3 þ T cells. No post transplant pharmacological immunosuppression was administered to patients with completely T-cell-depleted grafts. Two patients with unrelated donors received T cell add-backs at day 0 and were treated with a short course of cyclosporin A (CSA; 1-3 mg/kg body weight).
Flow cytometry
Reconstitution of CD3
þ and CD56 þ CD16 þ lymphocytes after transplantation was assessed weekly until day 100 and was subsequently assessed monthly.
Cell culture
The common-ALL cell line MHH4 and the Burkitt's lymphoma cell line Raji (German Collection of Microorganisms and Cell Cultures, DSMZ, Braunschweig, Germany) were maintained in RPMI 1640.
Primary leukemic blasts were obtained from a patient with common-ALL. Over 90% of bone marrow cells were positive for CD10/CD19/CD20/CD22/TdT as determined by flow cytometry.
Effector cells
PBMNC were obtained by standard Ficoll-Hypaque density gradient centrifugation. Enriched NK cells from healthy donors were purified by MACS separation as described elsewhere. 14 , Roche, Basel, Switzerland) at a concentration of 1 mg/ml for 30 min before adding the effector cells. As controls, effector cells and anti-CD20 alone were used to exclude direct cytotoxic effects (lysiso10% in all experiments). CDC was performed by replacing of 50 ml medium by the same amount of patient-derived serum (serum: medium ¼ 1 : 3). The assays were continued as published.
Cytotoxicity assay
14 Specific lysis was calculated as follows: % specific lysis ¼ (experimental releaseÀspontaneous release)/(maximum releaseÀspontaneous release) Â 100.
Statistical analysis
Differences in specific lysis with and without antibody incubation were analyzed by the paired t-test using NCSS software.
Results
Immune reconstitution of NK and T cells after transplantation
Reconstitution of CD3
þ and CD56 þ CD16 þ lymphocytes after transplantation with CD34 þ selected cells was monitored by flow cytometry for 18 out of those 19 patients whose effectors were used to test ADCC against Raji and MHH cells. Mean values of CD3 þ percentages remained below 20% of lymphocytes (o100 CD3 þ /ml) in the first 2 months after transplantation and returned to the normal range after approximately 1 year. By contrast, the recovery of CD56 þ CD16 þ cells was rapid: a clear NK cell peak with percentages 480% (mean cell count: 346 cells/ml) was observed as early as 1-2 months after transplantation. At later times NK cell percentages and absolute cell counts decreased to normal levels ( Figure 1 ) and T cells were predominant.
Temporal development of cytotoxic activity of effector cells from transplanted patients
ADCC by anti-CD20 (rituximab) was measured with MNC as effectors recovered from the same patients (n ¼ 19) at various times after transplantation against Raji ( Figure 2a ) and/or MHH4 targets (Figure 2b ). A total of n ¼ 30 experiments were carried out (Raji: n ¼ 18, MHH: n ¼ 12). 9/19 patients were tested once. 10/19 patients were tested in more than one time period or against different targets (Table 1) 
Cytotoxic activity of MNC from transplanted patients compared with healthy donors against MHH4 and Raji target cells
In addition, we analyzed the cytotoxic activity of effector cells obtained from patients in the early post transplant phase (1-4 months) and compared these results with the lytic activity of MNCs from eight healthy donors. Experiments were carried out within this period for five out of the 19 patients. Mean specific lyses at various E : T ratios are shown in Figure 3 .
Neither unstimulated nor IL2-stimulated MNCs from healthy donors were capable of exerting significant lysis of MHH4 and Raji targets. However, preincubation of the target cells with anti-CD20 clearly increased specific lysis, which was further augmented by stimulation of effector cells with IL2. (Raji: 27 and 38.5%; MHH: 25 and 39%; E : T ratio ¼ 20 : 1; P-values see Figure 3a and b). No lysis was observed when rituximab was used without effector cells, indicating that the antibody itself had no direct cytotoxic effects (mean lysis ¼ 5% (MHH)/6% (Raji)). In vitro antileukemic activity in pediatric patients M Pfeiffer et al
Similar results were obtained with patient-derived effectors:
In the absence of anti-CD20, none of the patients exerted significant lysis; preincubation with anti-CD20 enhanced specific lysis in four out of five patients (P-values see Figure  3c and d). Interestingly, IL2 stimulated patient's MNC had a tendency to be even more effective than those of the control group (MHH targets: 80 vs 39%, Po0.01; Raji targets: 47 vs 38,5%, P ¼ 0.3). This finding may be explained by the high percentage of circulating NK cells in our patients.
Cytotoxic activity of purified donor-NK cells and of patient-derived MNCs against cryopreserved leukemic blasts
Cryopreserved CD20 þ leukemic blasts from a pediatric patient with common ALL were used as targets. Unstimulated enriched NK cells from four healthy donors showed strong cytolytic activity against leukemic blasts. Lysis was further augmented with anti-CD20. This indicates that ADCC reactions were mainly mediated by NK cells. The most important question was whether patient-derived effector cells were capable of lysing patient-derived leukemic blasts in combination with anti-CD20. Without anti-CD20, only low specific lysis with both unstimulated and IL2 stimulated effectors was obtained. Preincubation of target cells with anti-CD20 clearly increased specific lysis in each of the patients (four experiments with MNCs from three different patients obtained within period one after transplantation; P-values see Figure 4 ). As a control, an irrelevant humanized antibody (CH14/18) was used, which did not significantly enhance lysis, indicating that anti-CD20 mediated lysis was specific.
Additional effect of complement-dependent cytotoxicity
Replacing 50 ml medium by the same amount of patientderived, autologous serum in the cytotoxicity assay (serum : medium ¼ 1 : 3) additionally enhanced specific lysis of leukemic blasts ( Figure 5 ), whereas no effect was observed with heat-inactivated serum. Combination of ADCC and CDC had additive effects, which should be of high relevance in vivo: since complement is normally present in peripheral blood, we expect even more effective lysis in vivo than in vitro. Incubation of target cells with rituximab without effector cells or serum did not exert any lysis, indicating that other previously described mechanisms such as apoptosis induction did not play an important role in this in vitro setting.
Discussion
The efficacy and safety of rituximab for eradication of minimal residual disease after autologous stem cell ) and to a lesser extent in B-CLL. 8 Although there are different mechanisms of action of rituximab in the elimination of tumor cells in vivo, it is generally accepted that complementdependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) are major components. [9] [10] [11] [12] Less is known about the potential usefulness of therapeutic antibodies and their effects on the donorderived immune system in allogeneic transplanted patients. Here, we demonstrated that effector cells and complement from pediatric patients after transplantation of T-celldepleted stem cells were capable of eliciting both ADCC and CDC with the chimeric CD20 antibody rituximab against CD20 þ B-lineage leukemia cell lines and also against primary pediatric ALL blasts from our patients. These cryopreserved blasts were most effectively lysed by the combination of ADCC and CDC and both mechanisms appeared to be of similar importance. In ADCC reactions, we found a temporal development: highest lytic activity of patient-derived effector cells was observed in the first months after transplantation against lymphoblastic CD20 þ MHH4 and Raji cells in the presence of rituximab, and this activity corresponded to the high percentage of regenerating CD56 þ CD16 þ cells. Moreover, purified donor NK cells also efficiently lysed our CD20 þ primary ALL blasts with the help of rituximab. Both observations indicate that NK cells are likely to be the major effectors of ADCC reactions. In haploidentical transplantations, NK cell alloreactivity due to killer cell immunoglobulin-like receptor (KIR) ligand incompatibility has also been reported. Remarkable NK-cell-based GvL effects were observed in acute myeloic leukemias (AML), but not in ALL. 16 Therefore, in particular ALL patients may benefit from antibody-augmented GvL effects.
An early-acting immunotherapy based on the recruitment of these rapidly regenerating NK cells might help to prevent relapse caused by minimal residual leukemic cells, since the majority of relapses occur during the first 6 months after transplantation. IL2 additionally augmented the effects of ADCC in rituximab mediated lysis in our study and in others 17 and was well tolerated in combination with rituximab infusion in vivo. 18 Therefore, a combined approach of both IL2 and rituximab-infusion might also be considered for the post transplant treatment of minimal residual leukemia cell loads. Recently, a study from Shimoni et al 13 showed a high rate of disease free survival for patients with high-risk non-Hodgkin's lymphoma who were treated with rituximab after autologous or allogeneic transplantation. They also reported episodes of neutropenia associated with hypogammaglobulinemia. Moreover, CD20 antibodies can cause a prolonged deficiency of donor-derived nonmalignant B cells. However, these side effects might be overcome by substitution with immunoglobulins and by additional infusions of cryopreserved CD34 þ selected donor stem cells after immunotherapy (stem cell boosts), which are expected to reconstitute a complete hematopoietic system, including the B cell lineage. 19 In patients with B-CLL rituximab monotherapy had limited activity 20 and mainly resulted in partial and transient responses. This observation may be explained by the high tumor cell load of such patients with relapsed or refractory disease. 8 In contrast, after allogeneic transplantation the leukemia cell load should be reduced to a minimum, which argues in favor of immunotherapeutic approaches based on specific antibodies.
In our experience, only 12% of pro-B, pre-B and common-ALLs were positive for CD20. Thus, CD19 may be the more suited antigen for the treatment of pediatric B-lineage leukemias, as it is consistently and uniformly expressed in these malignancies. 21 We have recently shown the efficacy of a chimeric CD19 antibody in mediating ADCC in vitro. 22 On the other hand, therapeutic protocols employing anti-CD20 are already a clinical reality, and therefore, post transplant treatment of pediatric CD20 þ lymphatic leukemias with rituximab should be easily practicable and should now be evaluated in clinical studies.
In summary, we have shown that rituximab mediated effective ADCC and CDC against CD20 þ leukemic targets with NK cells and complement from children who received T-cell-depleted allografts. High-NK cell activities were detected already in the first few months after transplantation, providing the possibility of early post transplant intervention. These findings encourage clinical trials in patients with CD20
þ leukemias in an attempt to control minimal residual disease and to prevent relapse with the help of the donor-derived immune system after high-risk allogeneic transplantation.
